Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations

MT Newswires Live

04/15

Can-Fite BioPharma (CANF) said Monday it expects to generate $685 million in projected future revenues from its collaborations.

The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.

The company said it also expects "substantial" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.

Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.

Price: 1.60, Change: +0.02, Percent Change: +1.59

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2527142311"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527142311\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527142311?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 02:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527142311","market":"hk","top_or_hot":-1,"title":"Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations","media":"MT Newswires Live","content":"<html><body><p> Can-Fite BioPharma (CANF) said Monday it expects to generate $685 million in projected future revenues from its collaborations.</p><p>The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.</p><p>The company said it also expects \"substantial\" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.</p><p>Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.</p><p>Price: 1.60, Change: +0.02, Percent Change: +1.59</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-04-15 02:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Can-Fite BioPharma (CANF) said Monday it expects to generate $685 million in projected future revenues from its collaborations.</p><p>The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.</p><p>The company said it also expects \"substantial\" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.</p><p>Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.</p><p>Price: 1.60, Change: +0.02, Percent Change: +1.59</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CANF","symbol_name":"Can-Fite Biopharma Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527142311","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527142311","pubTimestamp":1744654835,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Can-Fite BioPharma  said Monday it expects to generate $685 million in projected future revenues from its collaborations.The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.The company said it also expects \"substantial\" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.Price: 1.60, Change: +0.02, Percent Change: +1.59","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CANF":"Can-Fite Biopharma Ltd"},"translate_title":"Can-Fite BioPharma预计通过合作未来收入将达到6.85亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANF":0.9},"content_text":"Can-Fite BioPharma (CANF) said Monday it expects to generate $685 million in projected future revenues from its collaborations.The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.The company said it also expects \"substantial\" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.Price: 1.60, Change: +0.02, Percent Change: +1.59","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}